Domino's, JPMorgan, Liquidia Price Targets, October 14 2026
Domino’s Pizza
Domino’s Pizza is the largest pizza company in the world, based in Ann Arbor, Michigan. Most of its 22,706 stores are run by franchisees, and 15,449 of them sit outside the US. It reports three segments: US stores, international franchise and supply chain. The supply chain arm sells dough and ingredients to the stores, and franchisees pay royalties on sales. Global retail sales across the system reached $4.84 billion in the third quarter.
Domino’s reported third-quarter results before the open on Tuesday. Revenue came to $1.19 billion, against $1.15 billion a year earlier. Diluted earnings were $4.60 a share, against $4.08 a year before and a $4.36 consensus. Same store sales at US stores grew 0.3%. International same store sales, excluding currency, grew 0.2%. The chain added 175 net stores in the quarter. It was the first report under Joe Jordan as chief executive.
Ten Desks Act on Domino’s
Sara Senatore of BofA Securities kept her Buy rating and cut her target from $455 to $410 today, a Wednesday. Todd Brooks of StoneX also kept Buy, lowering his target from $430 to $400. Peter Saleh of BTIG reiterated Buy with a $425 target. Dennis Geiger of UBS reiterated Buy and a $385 target.
Six other desks acted on the stock. Brian Harbour of Morgan Stanley kept Equalweight and moved his target from $357 to $345. Chris O’Cull of Baird lowered his from $325 to $320. Zachary Fadem of Wells Fargo lowered his target from $350 to $320. Christopher Carril of KeyBanc reiterated Sector Weight. Logan Reich of RBC Capital lowered his target from $325 to $320. Andrew Strelzik of BMO Capital cut his to $390. Jon Tower of Citi had already cut his target to $308 after the report on Tuesday.
Domino’s Record on AnaChart
Domino’s draws 25 covering analysts on AnaChart. Their average target is $398.68, a figure that predates this morning’s cuts. The highest target on the site is $545 and the lowest is $315. Ratings split 54.64% Buy, 42.27% Hold and 3.09% Sell. AnaChart’s tracking shows 71.08% of Domino’s targets get met, after about 196 days on average. O’Cull has met 37 of his 46 Domino’s targets, an 80.43% hit rate, with an average potential upside of 0.91%.
JPMorgan Chase
JPMorgan Chase is the largest bank in the US. It takes deposits, makes loans and manages money for households, companies and governments. It runs consumer branches and credit cards under the Chase name, a corporate and investment bank, and an asset and wealth management arm. Third-quarter revenue came to $50.17 billion.
The bank reported before the open on Tuesday. Earnings were $5.75 a share, against a $5.93 consensus. Revenue also came in under the $51.23 billion estimate. Fixed income trading revenue also came in below forecasts.
Barclays Lifts JPMorgan to $425
Jason Goldberg of Barclays raised his JPMorgan target to $425 today, a Wednesday. He rates the stock Overweight. Christopher McGratty of Keefe, Bruyette & Woods reiterated Outperform with a $384 target. David George of Baird kept Neutral and raised his target from $305 to $312.
JPMorgan’s Record on AnaChart
JPMorgan draws 18 covering analysts on AnaChart. Their average target is $357.73, with a high of $420 and a low of $288. That average predates this morning’s notes. Ratings split 59.62% Buy, 38.46% Hold and 1.92% Sell. AnaChart’s tracking shows 90.42% of JPMorgan targets get met, after about 334 days on average.
Liquidia
Liquidia is a drug company in Morrisville, North Carolina. Its product is YUTREPIA, an inhaled powder form of treprostinil for pulmonary arterial hypertension, a disease of the arteries in the lungs. Its third-quarter revenue from YUTREPIA came to $222.7 million in net product sales, a preliminary figure. Full third-quarter results come in November.
The news came after the close on Tuesday. Liquidia settled all six pending lawsuits with United Therapeutics. It will make a net payment of $175 million within 30 business days. Another $145.4 million follows in two payments of $72.7 million, due by January 31 and April 30, 2027. A further $60.3 million goes to parties in a related antitrust case, for $380.7 million in total. The deal follows a September 30 ruling in Delaware that Liquidia infringed a patent covering one use of inhaled treprostinil. Liquidia will not appeal and will remove that use from YUTREPIA’s label. It held $396.1 million in cash at the end of September and said it can pay without new financing.
BTIG Upgrades Liquidia to Buy
Julian Harrison of BTIG upgraded Liquidia to Buy from Neutral today, a Wednesday, with a $70 target. Serge Belanger of Needham kept Buy and cut his target from $72 to $58. Benjamin Burnett of Wells Fargo raised his target from $30 to $33.
Liquidia’s Record on AnaChart
Liquidia draws nine covering analysts on AnaChart. Their average target is $54.63, with a high of $109 and a low of $19. Ratings split 93.55% Buy, with one Hold and one Sell on record. AnaChart’s tracking shows 91.99% of Liquidia targets get met, after about 420 days on average. Belanger has met 38 of his 39 Liquidia targets, with an average potential upside of 157.23%. Harrison has met 18 of 20, with an average potential upside of 40.88%. Burnett has met three of four, at 4.75%.
What the Performance Matrix Shows
Liquidia has the best met ratio of the three, just ahead of JPMorgan, and Domino’s the weakest. The waits run the other way. A Domino’s target lands soonest, and a Liquidia target takes the longest. The records differ in age too. AnaChart’s first JPMorgan forecast dates to February 2007, its first Domino’s forecast to February 2012 and its first Liquidia forecast to August 2018.
AnaChart tracks every price target against what happened to the stock afterward, desk by desk and analyst by analyst. The ticker pages linked above break out each record by analyst, firm and year. AnaChart’s full data set holds more than 760,000 analyst calls on more than 9,000 tickers, active and delisted. More than 680,000 carry a price target and more than 730,000 carry a rating. It is the second largest database of its kind. The raw file is available through the AnaChart store.
The previous update covered Nurix, Syndax and VF on October 13.
